Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study (BIO-PROSA)
Sponsor: Azienda Policlinico Umberto I
This observational or N/A phase trial investigates Breast Cancer and is currently actively recruiting participants. Azienda Policlinico Umberto I leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Recruiting
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Azienda Policlinico Umberto I
- Campus Bio-Medico University
- Catholic University of the Sacred Heart
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Hospital San Pietro Fatebenefratelli
- Ospedale Gaetano Bernabeo , Ortona
- Ospedale SS Annunziata, Chieti
- Ospedale Sandro Pertini, Roma
- Ospedale di Belcolle - Viterbo
- Regina Elena Cancer Institute
- San Giovanni Addolorata Hospital
- presidio Ospedaliero santo spirito in Sassia, Roma
For direct contact, visit the study record on ClinicalTrials.gov .